Table 2.
MDACC study | Silber model | |||||
Variable | Odds ratio | 95% CI | P | Odds ratio | 95% CI | P |
Radiotherapy + chemotherapy indicatora | - | 9.5 | 2.5–36.6 | 0.0011 | ||
Cycle 1 nadir ANC (× 109/liter) | 4.8 | 2.3–9.9 | <0.0001 | 4.4 | 2.1–9.2 | <0.0001 |
Cycle 1 hemoglobin decrease (g/dl) | 1.8 | 1.0–3.3 | 0.0686 | 1.8 | 1.2–2.8 | 0.0074 |
n | 143 | 95 | ||||
Model χ2 | 21.2 (2 df) | 30.3 (3 df) | ||||
Log-likelihood P | <0.0001 | <0.0001 | ||||
C-statistic | 0.78 | 0.83 | ||||
Hosmer–Lemeshow lack-of-fit P | 0.1268 | 0.6140 |
CI, confidence interval; df, degrees of freedom. aNot applicable to MDACC study because patients were not treated with concurrent radiotherapy.